The promise of artificial intelligence has long been hailed as a universal accelerator for discovery, yet the reality on laboratory benches tells a more nuanced story.
In disciplines where truth can be checked against formal rules, AI has already become a collaborative partner.
By contrast, biological and chemical experiments inhabit a world of noise, variability, and contingent outcomes that resist simple formalization.
A recent study from Google, Google DeepMind, and MIT FutureTech surveyed 637 scientists and found that 44% now cite later-stage activities – physical experimentation, data collection, and sample preparation – as their primary bottleneck.
The report reveals that roughly 89% of those who save time using AI spend more than a tenth of that saved time double-checking the model’s predictions.
This heterogeneity of verification tasks further clarifies why AI’s usefulness varies so starkly across fields.
Efforts to close the gap by automating the laboratory itself encounter formidable practical barriers.
Cost remains a decisive factor; state-of-the-art automated labs capable of running dozens of parallel biochemical assays can run into the millions of dollars.
The philosophical divide highlighted by Nobel laureate Daron Acemoglu underscores a deeper reason for the disparity: many biological questions lack a clean, objective ground truth against which AI can be measured.
Regulatory and safety norms further throttle the pace at which AI-accelerated ideas can be turned into usable knowledge.
Amid these constraints, pioneering efforts illustrate a path forward, such as Julius B. Lucks’ DREAM Cloud Lab at Northwestern.
From a market perspective, the uneven AI adoption is reshaping where venture capital and corporate R&D dollars flow.